Dimitrios Balomenos
National Center for Biotechnology/CSIC, Madrid, Spain.
Biography
Dimitrios Balomenos received his PhD of Rutgers University, NJ. And continued his postdoctoral training at the Scripps Research Institute (La Jolla, Ca) and in the Department of Immunology and Oncology of CNB/CSIC in Madrid,Spain. In 2002 he was awarded an independent group research contract and from 2010 he is a tenured group leader at CNB/CSIC. Major discoveries include the absolute requirement of IFN-gamma for Systemic Lupus Erythematosus pathogenesis, (D. Balomenos et al, J. Clin. Invest. 1997), the discovery of p21-dependent pathways for regulation of T cell tolerance and autoimmunity (D. Balomenos et al, Nat. Med. 2000), and the requirement for p21 in reprogramming of M1-to-M2 macrophages, though the regulation of p50/p50 NF-kB and IFN-beta expression (Rackov et al, J. Clin Invest 2016). The group focuses in understanding how p21 and other molecules restrain extreme immune responses and discover p21 molecular patners that control ecssessive infalmmation and might harbor potential treatment capacity.
Abstract
Abstract : P21 is a master regulator of nf-kb-dependent inflammation in immune disease and allergic asthma